Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) Return on Sales (2020 - 2025)

Historic Return on Sales for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to 1.82%.

  • Maxcyte's Return on Sales fell 4000.0% to 1.82% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.33%, marking a year-over-year decrease of 5400.0%. This contributed to the annual value of 1.06% for FY2024, which is 1400.0% down from last year.
  • Maxcyte's Return on Sales amounted to 1.82% in Q3 2025, which was down 4000.0% from 1.45% recorded in Q2 2025.
  • Over the past 5 years, Maxcyte's Return on Sales peaked at 0.26% during Q3 2021, and registered a low of 1.82% during Q3 2025.
  • For the 5-year period, Maxcyte's Return on Sales averaged around 0.92%, with its median value being 0.9% (2024).
  • In the last 5 years, Maxcyte's Return on Sales soared by 7400bps in 2022 and then plummeted by -9200bps in 2023.
  • Quarter analysis of 5 years shows Maxcyte's Return on Sales stood at 0.48% in 2021, then increased by 19bps to 0.39% in 2022, then increased by 13bps to 0.34% in 2023, then plummeted by -262bps to 1.22% in 2024, then tumbled by -49bps to 1.82% in 2025.
  • Its Return on Sales stands at 1.82% for Q3 2025, versus 1.45% for Q2 2025 and 0.99% for Q1 2025.